These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 744064)

  • 1. Experimental hypertension and other responses to 18-hydroxy-deoxycorticosterone treatment in the rat.
    Hall CE; Gomez-Sanchez CE; Holland OB; Nasseth D; Hall O
    Endocrinology; 1978 Jul; 103(1):133-40. PubMed ID: 744064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of 19-nor-deoxycorticosterone on blood pressure, saline consumption, and serum electrolytes, corticosterone, and renin activity.
    Hall CE; Gomez-Sanchez CE; Holland OB; Nasseth D
    Endocrinology; 1979 Sep; 105(3):600-4. PubMed ID: 157270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digoxin amplifies the effects of deoxycorticosterone acetate (DOCA) in intact water-drinking rats: implications for the mechanism of DOCA hypertension?
    Li M; Martin A; Liu DT; Whitworth JA
    J Hypertens; 1994 May; 12(5):569-76. PubMed ID: 7930557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 5 alpha-dihydrocortisol on the blood pressure of rats treated with deoxycorticosterone acetate and salt.
    Mikami H; Nugent CA; Ogihara T; Naka T; Iwanaga K; Kumahara Y
    Endocrinol Jpn; 1980 Dec; 27(6):769-73. PubMed ID: 7021137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morin attenuates blood pressure and oxidative stress in deoxycorticosterone acetate-salt hypertensive rats: a biochemical and histopathological evaluation.
    Prahalathan P; Kumar S; Raja B
    Metabolism; 2012 Aug; 61(8):1087-99. PubMed ID: 22386933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
    Ito H; Majima M; Nakajima S; Hayashi I; Katori M; Izumi T
    Br J Pharmacol; 1999 Feb; 126(3):613-20. PubMed ID: 10188971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary chloride does not correlate with urinary thromboxane in deoxycorticosterone acetate-treated rats.
    Theriot JA; Passmore JC; Jimenez AE; Fleming JT
    J Lab Clin Med; 2000 Jun; 135(6):493-7. PubMed ID: 10850649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a methionine-supplemented diet on the blood pressure of Sprague-Dawley and deoxycorticosterone acetate-salt hypertensive rats.
    Robin S; Maupoil V; Laurant P; Jacqueson A; Berthelot A
    Br J Nutr; 2004 Jun; 91(6):857-65. PubMed ID: 15182389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats.
    Silambarasan T; Raja B
    Eur J Pharmacol; 2012 Mar; 679(1-3):81-9. PubMed ID: 22266490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of potassium on blood pressure in DOCA salt hypertension in rats.
    Suzuki H; Kondo K; Saruta T
    Acta Endocrinol (Copenh); 1981 Aug; 97(4):525-32. PubMed ID: 7270008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DOCA-salt on angiotensin dependency and surgical reversal of hypertension in two-kidney, one clip renal hypertensive rats.
    Takata Y; Doyle AE
    J Hypertens; 1983 Jun; 1(1):57-63. PubMed ID: 6397514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ouabain as an amplifier of mineralocorticoid-induced hypertension.
    Sekihara H; Yazaki Y; Kojima T
    Endocrinology; 1992 Dec; 131(6):3077-82. PubMed ID: 1446641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiological role of renal dopamine and kallikrein in deoxycorticosterone acetate (DOCA)-salt treated rats.
    Ishiguro T; Shimamoto K; Ura N; Nomura N; Hayashi M; Iimura O
    Clin Exp Hypertens; 1995 Nov; 17(8):1287-99. PubMed ID: 8563702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural, functional and hypertensive effects of 19-oxo-11-deoxycorticosterone acetate (19-oxo-DOCA) in the rat.
    Hall CE; Gomez-Sanchez CE; Hungerford S
    Steroids; 1983 May; 41(5):627-35. PubMed ID: 6658894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice.
    Wang Q; Domenighetti AA; Pedrazzini T; Burnier M
    Hypertension; 2005 Sep; 46(3):547-54. PubMed ID: 16103267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between plasma 18-hydroxy-11-deoxycorticosterone levels and production of hypertension in the rat.
    Carroll J; Komanicky P; Melby JC
    J Steroid Biochem; 1981 Oct; 14(10):989-95. PubMed ID: 7300332
    [No Abstract]   [Full Text] [Related]  

  • 17. Lithium prevents saline deoxycorticosterone acetate (DOCA) hypertension in the rat.
    Iaina A; Shochat J; Serban I; Kapuler S; Gavendo S; Goldfarb D; Eliahou HE
    J Lab Clin Med; 1982 Feb; 99(2):231-8. PubMed ID: 6278037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension.
    Seto S; Nagao S; Ozeki S; Tetsuo H; Akahoshi M; Yano K
    J Cardiovasc Pharmacol; 2006 May; 47(5):680-5. PubMed ID: 16775508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
    Minato M; Honda M; Hatano M
    Nihon Naibunpi Gakkai Zasshi; 1990 Jan; 66(1):29-41. PubMed ID: 2307256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Endocrinology; 1986 Jun; 118(6):2582-7. PubMed ID: 3698922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.